Rxsight Inc

rxsight.com

What Do They Do?

Sells adjustable lenses and light-delivery devices to surgery centers, hospitals, and physician practices for cataract surgery.

How Do They Make Money?

Practices get revenue from LAL lenses when they report implantation; distributors when title transfers. Customers get billed for light-delivery devices at installation and acceptance or shipment; training after installation, and service agreements over time.

revenue

Segment	Share	How money arrives
L D D Mix	15% FY2022: 46%	Mix
LAL Sold outright	80% FY2022: 51%	Sold outright
Service Warranty, Service Contracts, And Accessories Recurring	4.3% FY2022: 3.1%	Recurring

Who Are Their Customers?

Surgery centers, hospitals and physician practices are customers; RxSight sells directly through its U.S. sales team and through international distributors.

Do Revenues Turn Into Profits?

No. It lost $38.9M in FY2025.

Operating income, FY2025

−36% of revenue

▲ +31% (Loss) vs FY2024 (−$36.9M, −26%)

Net income, FY2025

−29% of revenue

▲ +42% (Loss) vs FY2024 (−$27.5M, −20%)

Free cash flow, FY2025

−14% of revenue

▼ −14% (Loss) vs FY2024 (−$22.4M, −16%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▼ −19%; vs $33.6M in Q2 FY2025
Net income: ▲ +3% (Loss); vs −$11.8M in Q2 FY2025

Aug 5, 2026 Withdrew 2026 financial guidance RxSight withdrew its 2026 guidance during the leadership transition and said it would resume formal guidance in early 2027.
Jul 15, 2026 Appointed Aziz Mottiwala as CEO Mottiwala was appointed president and CEO, while Kurtz is to become chief medical officer.
Jul 6, 2026 Agreed with Alcon to develop adjustable lenses Alcon will commercialize the products; RxSight will develop and manufacture them and receive a $60 million upfront payment, potential milestone payments and sales royalties.

Growing. Revenue grew 6.0x in 4 years, from $22.6M in FY2021 to $134.5M in FY2025, about 56% a year.

Integrated customer support The latest report describes a unified Customer Success Organization combining clinical and sales teams to support practices from onboarding through ongoing lens use; the older report described separate sales, account-management, clinical and service roles.

Revenue over time

L D D LAL Service Warranty, Service Contracts, And Accessories

$200M$100M$0

FY2022 FY2023 FY2024 FY2025

Who Do They Compete With?

Competes with Alcon and Johnson & Johnson

Comments